SCHEMBL16474222

SCHEMBL16474222

CCN1CCN(c2ccc(-c3nc(O)c4nc[nH]c4n3)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 2/20 0.50
ACHE P22303 1/20 0.43
FGFR1 P11362 1/20 0.43
FGFR2 P21802 1/20 0.43
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
RAD52 P43351 1/20 0.41
GFER P55789 1/20 0.41
JAK2 O60674 1/20 0.40
CHRNA7 P36544 1/20 0.40
SYK P43405 3/20 0.39
PTK2 Q05397 2/20 0.39
KDM1A O60341 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14233654 0.87 ADORA1 (0.49) TLR9KDM4ERAB9A
SCHEMBL16474221 0.86 TLR9 (0.50) TLR9ACHEFGFR1FGFR2MAPT
SCHEMBL16474226 0.78 TLR9 (0.76) TLR9
SCHEMBL14233909 0.76 ACHE (0.53) TLR9ACHEMAPTSMN1; SMN2KDM4E
SCHEMBL16474223 0.75 ADORA3 (0.47) MAPTSMN1; SMN2GAA
SCHEMBL14233661 0.73 ADORA1 (0.49) TLR9KDM4ERAB9AMTOR
SCHEMBL28084733 0.73 TLR9 (0.47) TLR9MAPTKDM4EGAAGFER
SCHEMBL14104420 0.72 MEN1 (0.40) SMN1; SMN2NPC1RAB9A
SCHEMBL16146680 0.72 ADORA3 (0.44) MAPTSMN1; SMN2KDM4EGAARAB9A
SCHEMBL5162476 0.71 GAA (0.61) TLR9ACHEMAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353115-B2 Immune system modulators JANUS BIOTHERAPEUTICS, INC. (US) 2016-05-31 US disclosed
US-9353115-B2 Immune system modulators JANUS BIOTHERAPEUTICS, INC. (US) 2016-05-31 US disclosed
EP-2713737-B1 NOVEL IMMUNE SYSTEM MODULATORS JANUS BIOTHERAPEUTICS INC (US) 2016-04-20 EP disclosed
US-20140107115-A1 NOVEL IMMUNE SYSTEM MODULATORS JANUS BIOTHERAPEUTICS, INC. (US) 2014-04-17 US disclosed
US-20140107115-A1 NOVEL IMMUNE SYSTEM MODULATORS JANUS BIOTHERAPEUTICS, INC. (US) 2014-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107115-A1 NOVEL IMMUNE SYSTEM MODULATORS HLA-DRB1, CD47, MYD88 TLR9 19/4885ACHE 3450/4885FGFR1 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.